ftInvstr
IOLCP · Healthcare ₹199.5 +1.68% Mkt Cap ₹5824 Cr

IOLCP

Healthcare Drug Manufacturers - Specialty & Generic
₹199.5
+1.68% today · 30d +20.91%
as of 2026-09-04
Price · Daily Candles
“IOL Chemical & Pharma's Q4 Surge: Promoter Stake Jumps Amidst Strong Profit Growth.”
IOL Chemicals and Pharmaceuticals (IOLCP) closed Q4 2026 with a significant turnaround, posting a 69.19% YoY net profit increase to ₹53 Cr and a 17.37% YoY revenue jump to ₹619 Cr. This robust quarterly performance pushed the stock to a 41.22% return over the last month. However, its 3-year net profit CAGR remains negative at -0.36%.
BULL CASE
+Net profit surged by 69.19% YoY in Q4 2026 to ₹53 Cr, demonstrating strong operational recovery.
+Quarterly revenue saw a substantial increase of 17.37% YoY, reaching ₹619 Cr, indicating growing demand.
+Promoter shareholding increased by 4.86 percentage points QoQ to 57.48% as of March 2026, signaling confidence.
+The stock has delivered impressive short-term returns, with a 1-month return of 41.22% and a 3-month return of 74.99%.
BEAR CASE
Despite recent gains, the 3-year net profit CAGR stands at -0.36%, suggesting historical earnings volatility.
The 5-year net profit CAGR is significantly negative at -20.9%, highlighting longer-term profitability challenges.
FII holdings decreased by 0.36 percentage points QoQ to 1.72% in Q4 2026.
The company's ROCE of 11.0% is significantly lower than some sector peers like SUNPHARMA (22.46%) and CIPLA (25.09%) indicating lower capital efficiency.
⟳ What Changed
₹ Latest Earnings · Q ending 2026-03-31
REVENUE
₹619 Cr
+17.37% YoY
NET PROFIT
₹53 Cr
+69.19% YoY
OPM
15.18%
+2.54pp YoY
EPS
₹1.81
PE 27.5
Intrinsic value · DCF: N/A — ML model predicts severe Δ FCF compression (h1=-39.1%, h2=-38.1%, h3=-41.5% of mktcap), driving projected FCF negative by year 3 despite healthy current FCF. Treating as forecast outlier rather than reporting a misleading ₹0 valuation. Use the Strategy Fit and ML sections instead.
◇ Sector Position
IOLCP's PE ratio of 27.5 is below peers like DIVISLAB (68.92) but its ROCE of 11.0% lags behind the sector, with leaders like DRREDDY at 27.63%.
PEERPEROCE %
IOLCP27.511.0
SUNPHARMA39.522.46
DIVISLAB68.9221.47
CIPLA29.1725.09
+ 2 more peers — sign in to view
ML Forward Growth Predictions 🔒

9 ML-predicted forward-growth ranks across sales, EBIT, and FCF.

Sign up freeSign in
70
SCORE / 100
Overall
6-axis composite of the sections below.
Performance STRONG 100
Valuation REASONABLE 60
Growth STRONG 72
Profitability DECENT 68
Technicals NEUTRAL 68
Risk MODERATE 50
Key Stats
TTM PE
27.5
P/B
2.16
52W HIGH
₹204.98
OFF HIGH
-2.67%
DIV YIELD
0.78%
MKT CAP
₹5824 Cr
◉ Active Signals
MACDBullish2.0205
RSI(14)Bearish73.59
Near 52W HighBullish-2.67
Street Consensus
1 analyst
₹150.0
mean target
Low ₹150.0Now ₹199.5High ₹150.0
⧉ Strategy Fit 🔒

See which of ftInvstr's 50+ strategies hold IOLCP and at what entry.

Sign up freeSign in